2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with B16 Melanoma in 10 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Berberine is a natural compound extracted from Coptidis rhizoma, and accumulating proof has shown its potent anti-tumor properties with diverse action on melanoma cells, including inhibiting cancer viability, blocking cell cycle and migration." | 7.83 | Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells. ( Du, B; Kou, Y; Li, B; Li, H; Li, L; Tan, Y; Wang, K, 2016) |
| "Berberine is a natural compound extracted from Coptidis rhizoma, and accumulating proof has shown its potent anti-tumor properties with diverse action on melanoma cells, including inhibiting cancer viability, blocking cell cycle and migration." | 3.83 | Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells. ( Du, B; Kou, Y; Li, B; Li, H; Li, L; Tan, Y; Wang, K, 2016) |
| " In order to evaluate the depigmenting capacity of diosgenin and elucidate its mechanism of action, several experiments were performed in B16 melanoma cells." | 3.74 | Diosgenin inhibits melanogenesis through the activation of phosphatidylinositol-3-kinase pathway (PI3K) signaling. ( Jung, K; Kim, YS; Lee, J; Park, D, 2007) |
| "ZSTK474 is a new PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in critical organs." | 1.33 | Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. ( Fukui, Y; Gouda, H; Hirono, S; Koshimizu, I; Matsuno, T; Yaguchi, S; Yamazaki, K; Yamori, T; Yoshimi, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kou, Y | 1 |
| Li, L | 1 |
| Li, H | 1 |
| Tan, Y | 1 |
| Li, B | 1 |
| Wang, K | 1 |
| Du, B | 1 |
| Cheli, Y | 1 |
| Luciani, F | 1 |
| Khaled, M | 1 |
| Beuret, L | 1 |
| Bille, K | 1 |
| Gounon, P | 1 |
| Ortonne, JP | 2 |
| Bertolotto, C | 2 |
| Ballotti, R | 2 |
| Harfouche, R | 1 |
| Basu, S | 1 |
| Soni, S | 1 |
| Hentschel, DM | 1 |
| Mashelkar, RA | 1 |
| Sengupta, S | 1 |
| Wang, P | 1 |
| Wang, X | 1 |
| Wu, P | 1 |
| Zhang, J | 1 |
| Sato, T | 1 |
| Yamagata, S | 1 |
| Yamagata, T | 1 |
| Huang, YC | 1 |
| Yang, CH | 1 |
| Chiou, YL | 1 |
| Bedogni, B | 1 |
| O'Neill, MS | 1 |
| Welford, SM | 1 |
| Bouley, DM | 1 |
| Giaccia, AJ | 1 |
| Denko, NC | 1 |
| Powell, MB | 1 |
| Yaguchi, S | 1 |
| Fukui, Y | 1 |
| Koshimizu, I | 1 |
| Yoshimi, H | 1 |
| Matsuno, T | 1 |
| Gouda, H | 1 |
| Hirono, S | 1 |
| Yamazaki, K | 1 |
| Yamori, T | 1 |
| Lee, J | 1 |
| Jung, K | 1 |
| Kim, YS | 1 |
| Park, D | 1 |
| Buscà, R | 1 |
| Wellbrock, C | 1 |
| Fischer, P | 1 |
| Schartl, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)[NCT00555256] | Phase 1 | 19 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and B16 Melanoma
| Article | Year |
|---|---|
Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells.
Topics: Animals; Antineoplastic Agents; Berberine; Chromones; Epithelial-Mesenchymal Transition; Gene Expres | 2016 |
{alpha}MSH and Cyclic AMP elevating agents control melanosome pH through a protein kinase A-independent mechanism.
Topics: alpha-MSH; Animals; Chromones; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Enzyme Inhibitors; | 2009 |
Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cells, Cultured; | 2009 |
GM3 Upregulation of matrix metalloproteinase-9 possibly through PI3K, AKT, RICTOR, RHOGDI-2, and TNF-A pathways in mouse melanoma B16 cells.
Topics: Animals; Cell Line, Tumor; Cell Migration Assays; Cell Movement; Chromones; Enzyme Inhibitors; Gangl | 2011 |
Citrus flavanone naringenin enhances melanogenesis through the activation of Wnt/β-catenin signalling in mouse melanoma cells.
Topics: Animals; beta Catenin; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Cell Survival; Chr | 2011 |
Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice.
Topics: Administration, Topical; Animals; Butadienes; Chromones; Down-Regulation; Endothelium, Vascular; Enz | 2004 |
Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
Topics: Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, | 2006 |
Diosgenin inhibits melanogenesis through the activation of phosphatidylinositol-3-kinase pathway (PI3K) signaling.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Survival; Chromones; Diosgenin; Enzyme Inhibitors | 2007 |
Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation.
Topics: Animals; Cell Differentiation; Chromones; Colforsin; Cyclic AMP; Enzyme Inhibitors; Melanoma, Experi | 1996 |
PI3-kinase is involved in mitogenic signaling by the oncogenic receptor tyrosine kinase Xiphophorus melanoma receptor kinase in fish melanoma.
Topics: Amino Acid Sequence; Androstadienes; Animals; Binding Sites; Chromones; Enzyme Activation; Fish Prot | 1999 |